We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Test for C Difficile Toxins

By HospiMedica staff writers
Posted on 17 Oct 2005
A new test directly detects Clostridium difficile toxins A and B from fecal samples in only 20 minutes.

Until recently, all toxigenic strains of C difficile were thought to produce both toxins A and B, and toxin A was thought to play the most significant role in disease progression. More...
New reports now document the existence of A-/B+ strains of C difficile linked to C difficile-associated disease (CDAD). The ability to detect both toxins quickly is now extremely important, as reports from around the world increasingly report CDAD caused by strains that are negative for toxin A but positive for toxin B.

The new test, from Oxoid (Basingstoke, UK), is called Xpect Clostridium difficile toxin A/B test and it detects both toxins A and B. This minimizes false-negatives caused by A-/B+ strains. The test is simple, with no specimen processing required and minimal manual intervention. Diluted sample is mixed with conjugate and added to the test cassette. Within 20 minutes, the result is clearly visible. Such speed results in early therapy and prompt initiation of infection-control procedures.

Toxigenic C difficile strains are a frequent cause of infectious nosocomial diarrhea associated with recent antibiotic therapy. Those most at risk include the elderly, patients with underlying illnesses, and immunosuppressed patients. Complications include pseudomembranous colitis (PMC), toxic megacolon, perforations of the colon, sepsis, and even death. C difficile infection in a hospital increases morbidity and mortality among patients, increases therapeutic interventions and infection-control procedures, and increases length of stay for affected patients.




Related Links:
Oxoid

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.